Description
Creative Biolabs enhances the binding ability of the anti-VEGFR2 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the antibody.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced VEGFR2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
vascular endothelial growth factor receptor 2
Background
Kinase Insert Domain Receptor; Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase); Vascular Endothelial Growth Factor Receptor 2; Protein-Tyrosine Kinase Receptor Flk-1; Fetal Liver Kinase 1; EC 2.7.10.1; VEGFR2; FLK1; Tyrosine Kinase Growth Factor Receptor;
Antibody Clone
AES-0622-ZP996
Description
Creative Biolabs enhances the binding ability of the anti-VEGFR2 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.
